Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic Focal Segment Glomerulosclerosis: A Two Part Prospective Study of H.P. Acthar (PODOCYTE)
A study for patients with Focal Segmental Glomerulosclerosis (FSGS) using study drug Acthar
Sponsor: Mallinckrodt
Enrolling: Male and Female Patients
IRB Number: AAAQ6352
U.S. Govt. ID: NCT02633046
Contact: Wooin Ahn, MD: 212-305-0320 / wa2197@cumc.columbia.edu
Additional Study Information: Focal Segmental Glomerulosclerosis (FSGS) is a disease in which your kidneys allow an excess amount of protein in your urine. Too much protein in the urine (also called proteinuria) is a medical condition called nephrotic syndrome. The purpose of this clinical trial is to evaluate the safety and effectiveness of the study drug, Acthar, in adult patients with FSGS who have failed prior treatments.
This study is closed
Investigator
Wooin Ahn, MD
Do You Qualify?
Are you at least 18 years of age? Yes No
Have you been diagnosed with Focal Segmental Glomerulosclerosis (FSGS)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Wooin Ahn, MD
wa2197@cumc.columbia.edu
212-305-0320